Celia Rosario Dominguez

US Patent:

20090181943, Jul 16, 2009

Filed:

Apr 9, 2008

Appl. No.:

12/100200

Inventors:

Pierre Tessier - Hawkesbury, CA
Silvana Leit - Kirkland, CA
David Smil - Montreal, CA
Robert Deziel - Mount-Royal, CA
Alain Ajamian - Montreal, CA
Yves Andre Chantigny - Pincourt, CA
Celia Dominguez - Los Angeles CA, US

Assignee:

METHYLGENE INC. - Montreal

International Classification:

A61K 31/553
C07D 307/78
A61K 31/343
C07C 233/01
A61K 31/164
C07D 211/32
A61K 31/445
C07D 249/04
A61K 31/4192
C07C 311/15
A61K 31/18
C07D 235/04
A61K 31/4184
C07D 285/12
A61K 31/433
C07D 241/04
A61K 31/495
C07D 403/02
A61P 37/00
A61P 9/00
A61P 29/00
A61P 3/10
A61P 35/00
C12N 9/99
A61K 31/496
C07D 279/12
A61K 31/54
C07D 295/00
A61K 31/5375
C07D 213/56
A61K 31/44
C07D 219/02
A61K 31/435
C07D 267/16

US Classification:

51421113, 549467, 514469, 564161, 514617, 546233, 514331, 548255, 514359, 564 91, 514604, 5483047, 514394, 548136, 514363, 544393, 51425503, 544295, 51425214, 544 59, 5142275, 544162, 5142392, 546337, 514357, 546102, 514297, 540551, 435184

Abstract:

This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula compounds of the Formula (I)and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein groups L, M, X and Y are as defined herein.

US Patent:

20120302539, Nov 29, 2012

Filed:

May 7, 2012

Appl. No.:

13/466018

Inventors:

Michael Prime - Abingdon, GB
Stephen Martin Courtney - Stanford in the Vale, GB
Richard Marston - Wantage, GB
Celia Dominguez - Los Angeles CA, US
Douglas Macdonald - Los Angeles CA, US
John Wityak - Carlsbad CA, US

International Classification:

A61K 31/4468
C07D 405/12
A61K 31/453
C07D 207/48
A61K 31/40
A61K 31/4525
C07D 409/12
A61K 31/4535
C07D 401/12
A61K 31/454
C07D 405/14
C07D 205/04
A61K 31/397
A61K 31/4545
C07D 401/14
A61K 31/496
C07D 413/12
A61K 31/5377
A61P 25/28
A61P 1/16
A61P 13/12
A61P 25/00
A61P 35/04
A61P 35/02
A61P 35/00
A61P 37/00
A61P 29/00
A61P 19/02
A61P 17/06
A61P 9/00
A61P 9/10
A61P 3/10
A61P 17/10
A61P 27/12
A61P 27/10
A61P 21/00
A61P 17/02
A61P 1/00
A61P 25/14
A61P 25/16
C07D 211/96

US Classification:

51421001, 546224, 514329, 546203, 514325, 546207, 514326, 548542, 514424, 546205, 514320, 546196, 546214, 546202, 514324, 546201, 514323, 546208, 548953, 546189, 514316, 544364, 514319, 546213, 51425312, 544130, 5142355

Abstract:

Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

US Patent:

20130029988, Jan 31, 2013

Filed:

Jan 20, 2011

Appl. No.:

13/575019

Inventors:

Celia Dominguez - Los Angeles CA, US
Leticia M. Toledo-Sherman - Santa Monica CA, US
Dirk Winkler - Hamburg, DE
Frederick Brookfield - Oxfordshire, GB
Paula C. De Aguiar Pena - Oxfordshire, GB

International Classification:

C07D 403/04
A61K 31/505
A61K 31/506
C07D 413/04
C07D 413/14
A61P 25/08
C07D 401/04
A61K 31/513
C07D 417/04
A61P 25/28
A61P 25/16
A61P 25/00
C07D 239/28
A61K 31/5377

US Classification:

5142362, 544242, 514256, 544333, 544122, 544328, 544296, 514269, 514274, 544295, 51425214

Abstract:

Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

US Patent:

20130116216, May 9, 2013

Filed:

Nov 12, 2010

Appl. No.:

13/509783

Inventors:

Celia Dominguez - Los Angeles CA, US
John Wityak - Carlsbad CA, US
Michael Prime - Oxfordshire, GB
Stephen Martin Courtney - Oxfordshire, GB
Christopher Yarnold - Oxfordshire, GB
Frederick Brookfield - Oxfordshire, GB
Richard Marston - Oxfordshire, GB
Douglas Macdonald - Los Angeles CA, US

International Classification:

A61K 31/55
A61K 31/496
C07D 401/02
A61K 31/45
C07D 413/02
C07D 403/04
A61K 31/5377
A61K 31/495

US Classification:

514157, 544383, 435184, 514156, 51425212, 546244, 548531, 514423, 560159, 514155, 548453, 546153, 544131

Abstract:

Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

US Patent:

20220372045, Nov 24, 2022

Filed:

Apr 26, 2022

Appl. No.:

17/729881

Inventors:

- New York NY, US
Celia Dominguez - Los Angeles CA, US
Jonathan Bard - New York NY, US
Vinod Khetarpal - Ambler PA, US
Ashley Jarvis - Abingdon, GB
Sarah Hayes - Oxfordshire, GB
John E. Mangette - Town of Lancaster NY, US

International Classification:

C07D 498/04
A61K 51/04

Abstract:

Provided herein are certain compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.

US Patent:

20200397782, Dec 24, 2020

Filed:

Jun 10, 2020

Appl. No.:

16/898239

Inventors:

- New York NY, US
Celia Dominguez - Los Angeles CA, US
Vinod Khetarpal - Ambler PA, US
Travis Lee Houston - Lafayette IN, US
Stephan D. Parent - West Lafayette IN, US
Charlie Montgomery - Bolton MA, US
Geetha Banda - Wilmington NC, US

International Classification:

A61K 31/505
C07D 239/28

Abstract:

Forms of 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid (Compound I) were prepared and characterized in the solid state:Also provided are processes of manufacture and methods of using the forms of Compound I and salts or co-crystals thereof.

US Patent:

20190202795, Jul 4, 2019

Filed:

Jul 26, 2018

Appl. No.:

16/046254

Inventors:

- New York NY, US
Perla Breccia - Saffron Walden, GB
Celia Dominguez - Los Angeles CA, US
Alan F. Haughan - Saffron Walden, GB
Amanda Van de Poël - Saffron Walden, GB
Andrew J. Stott - Saffron Walden, GB
Christopher A. Luckhurst - Saffron Walden, GB
Elizabeth A. Saville-Stones - Saffron Walden, GB
Grant Wishart - Saffron Walden, GB
Michael Wall - Saffron Walden, GB
Rebecca E. Jarvis - Saffron Walden, GB

International Classification:

C07D 271/06
C07D 413/12
C07D 471/04

Abstract:

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.

US Patent:

20190185463, Jun 20, 2019

Filed:

Jul 26, 2018

Appl. No.:

16/046268

Inventors:

- New York NY, US
Perla Breccia - Saffron Walden, GB
Celia Dominguez - Los Angeles CA, US
Alan F. Haughan - Saffron Walden, GB
Rebecca E. Jarvis - Saffron Walden, GB
Christopher A. Luckhurst - Saffron Walden, GB
Elizabeth A. Saville-Stones - Saffron Walden, GB
Andrew J. Stott - Saffron Walden, GB
Amanda Van de Poël - Saffron Walden, GB
Michael Wall - Saffron Walden, GB
Grant Wishart - Saffron Walden, GB

International Classification:

C07D 413/12
C07D 491/107

Abstract:

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.